Congress Materials – American College of Gastroenterology (ACG 2025)
2025 American College of Gastroenterology | Oct 24-29 | Phoenix, AZ
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Comparison of Serum IL-22 and Tissue Molecular Changes Between guselkumab Subcutaneous and Intravenous Induction in Moderately to Severely Active Crohn’s Disease: Post Hoc Analysis of the GRAVITI and GALAXI Studies
Klebea Sohn, Dylan Richards, Ruchi Patel, Amy Hart, Christopher Sisk, Mobolaji Olurinde, Natalie A. Terry, Bradford McRae, Walter Reinisch, Flavio Steinwurz, Remo Panaccione, Geert D’Haens, and Patrick Branigan
Effect of Guselkumab Subcutaneous Induction and Maintenance on Bowel Urgency and Abdominal Pain as Measured by the UC-PRO/SS in Participants With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ASTRO Study
Silvio Danese, Laurent Peyrin-Biroulet, Millie Long, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Mary Kavalam, Chenglong Han, Silke Jorgens, Lingjing Jiang, Hongyan Zhang, Tadakazu Hisamatsu, David T. Rubin, Jessica R. Allegretti
Effects of Subcutaneous Guselkumab Induction and Maintenance on Histologic Outcomes in Patients with Moderately to Severely Active Crohn’s Disease in GRAVITI, a Phase 3 Double-blind, Placebo-controlled, Treat-through Study
Geert R. D’Haens, Ailsa Hart, Remo Panaccione, Flavio Steinwurz, Qian Cao, Mobolaji Olurinde, Leonardo Salese, Patrick Branigan, Wilbert van Duijnhoven, Nat A. Terry, Silvio Danese, Tadakazu Hisamatsu, Bruce E. Sands
Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, In Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-ranging Trial
Vipul Jairath, Britta Siegmund, Lindsey Surace, Ngozi Erondu, Minhu Chen, Karen Chachu, Edouard Louis, Katsuyoshi Matsuoka, Jimmy Limdi, Edmund Arthur, Nicole Houck, Mary Ellen Frustaci, Joyce Zhan, Grazyna Rydzewska, Edward V. Loftus, Jr., Maria T. Abreu
Efficacy and safety of subcutaneous guselkumab induction and maintenance therapy in participants with ulcerative colitis: Results through Week 48 from the Phase 3 ASTRO study
Jessica R. Allegretti, Laurent Peyrin-Biroulet, Millie Long, Matthew Germinaro, Thomas Baker, Mary Kavalam, Yelina Alvarez, Karen Hertzog, Silke Jörgens, Hongyan Zhang, Lingjing Jiang, Tadakazu Hisamatsu, David T. Rubin, Silvio Danese
Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients with Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Results From GALAXI 1, 2, & 3 Long-term Extension
Anita Afzali, Douglas Wolf, Rupert Leong, Rian Van Rampelbergh, Wilbert van Duijnhoven, Christopher Busse, Tadakazu Hisamatsu, Julián Panés
Intravenous and Subcutaneous Guselkumab Induction Therapy Are Both Efficacious in Crohn’s Disease Patients With High Baseline Disease Severity: Results at Week 12 From the Phase 3 GALAXI and GRAVITI Studies
Bruce E. Sands, Tadakazu Hisamatsu, Anita Afzali, Natalie A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Jacqueline Yee, Wilbert van Duijnhoven, Ailsa Hart, Silvio Danese, Remo Panaccione
Efficacy of Guselkumab in Moderately to Severely Active Ulcerative Colitis by Extent of Disease and Inflammatory Burden: Subgroup Analysis of the Phase 3 QUASAR Maintenance Study
Jessica R. Allegretti, Tadakazu Hisamatsu, Brian Bressler, Laurent Peyrin-Biroulet, Matthew Germinaro, Shadi Yarandi, Nicole Shipitofsky, Ye Miao, Bruce E. Sands, David T. Rubin, Axel Dignass
Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn’s disease in the GALAXI Phase 3 Studies
Anita Afzali, Tadakazu Hisamatsu, David T. Rubin, Nat A. Terry, Rian Van Rampelbergh, Jacqueline Yee, Kitty Yuen Yi Wan, Zijiang Yang, Walter Reinisch, Bruce E. Sands, Silvio Danese, Remo Panaccione
Guselkumab Pharmacokinetics and Exposure-response Relationships Are Consistent Following Intravenous Versus Subcutaneous Induction in Participants with Crohn’s Disease
Geert R. D’Haens, Omoniyi J. Adedokun, Tae Eun Yang, Bruce E. Sands, Silvio Danese, Nat A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Marion L. Vetter, Tadakazu Hisamatsu, Remo Panaccione
Impact of Subcutaneous guselkumab Induction Therapy on Molecular Inflammation in Patients With Ulcerative Colitis: Results From the Phase 3 ASTRO Study
Swati Venkat, Sunandini Sridhar, Barbara Shaikh, Klebea Sohn, Jared Liu, Christopher Sisk, Bradford McRae, Yelina Alvarez, Tom Baker, Matthew Germinaro, Jessica R. Allegretti, Millie Long, David T. Rubin, Laurent Peyrin-Biroulet, Amy Hart, and Patrick Branigan
Induction Efficacy of Subcutaneous Guselkumab vs Advanced Therapies in Moderately-to-Severely Active Crohn’s Disease: A Bayesian Network Meta-Analysis
Myrlene Sanon, Agathe Neviere, Dominik Naessens, Gabriela Friedrich, Camille Chopard-Lallier, Zijiang Yang, Tim Hoops, Sumesh Kachroo, Katerina Papadimitropoulou
Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-controlled APEX Study
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
Investigating Unmet Needs Among Advanced Therapy-Naïve Patients with Crohn’s Disease Treated with Ustekinumab or Risankizumab
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Aditi Shah, Lilian Diaz, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio
Investigating Unmet Needs Among Advanced Therapy-Naïve Patients with Ulcerative Colitis Treated with Ustekinumab or Upadacitinib
Freddy Caldera, Maryia Zhdanava, Sumesh Kachroo, Aditi Shah, Lilian Diaz, Fengyi Jiang, Caroline Kerner, Dominic Pilon, Jennifer Seminerio
Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn’s Disease: Phase 3 Long-term Extension Data From GALAXI 2, GALAXI 3, and GRAVITI
Geert R. D’Haens, David T. Rubin, Anita Afzali, Ailsa Hart, Tadakazu Hisamatsu, Nat A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Jacqueline Yee, Wilbert van Duijnhoven, Chris Corbett, Elizabeth Merrall, Qian Cao, Remo Panaccione, Julián Panés, Flavio Steinwurz, Silvio Danese, Bruce E. Sands
Longer Sustained Remission in Crohn’s Disease With Guselkumab Versus Ustekinumab Treatment: Projections From a Disease Model
Mariya Dimova, Mi Jun Keng, Feng Pan, Dominik Naessens, Leonardo Salese, Zijiang Yang, Sumesh Kachroo, Mario Gomez, Myrlene Sanon
Maintenance of Endoscopic and Histologic Efficacy With Guselkumab for Ulcerative Colitis at Week 92 of the QUASAR Long-Term Extension Study
Tadakazu Hisamatsu, Julián Panés, Fernando Magro, Gary R. Lichtenstein, Jessica R. Allegretti, Brian Bressler, Waqqas Afif, Mark A. Samaan, Byong Duk Ye, Shadi Yarandi, Matthew Germinaro, Nicole Shipitofsky, Dwiti Pandya, Ye Miao, Hongyan Zhang, Axel Dignass, David T. Rubin, Bruce E. Sands
Molecular Differentiation of guselkumab and ustekinumab in Moderately to Severely Active Crohn’s Disease: Post hoc Analysis of the GALAXI 2 and 3 Phase 3 Studies
Dylan Richards, Klebea Sohn, Martha Zeeman, Ruchi Patel, Bradford McRae, Nat Terry, Marion Vetter, Walter Reinisch, Daniel Cua, and Patrick Branigan
Pharmacokinetics and Exposure-response Relationships of Guselkumab Intravenous or Subcutaneous Induction in Participants with Ulcerative Colitis
Laurent Peyrin-Biroulet, Zhenhua Xu, Jie Shao, Tadakazu Hisamatsu, Millie Long, Silvio Danese, Matthew Germinaro, Marion L. Vetter, Shadi Yarandi, Thomas Baker, Jessica R Allegretti, David T Rubin
Symptom and Quality of Life Benefits of Achieving Deep Remission: A Real-World Survey of Patients with Crohn’s Disease
Myrlene Sanon, Hannah Knight, Rachael Meadows, Alexa Russnak, Elise Wu, Sumesh Kachroo
Symptom and Quality of Life Benefits of Achieving Deep Remission: A Real-World Survey of Patients with Ulcerative Colitis
Hannah Knight, Myrlene Sanon, Rachael Meadows, Alexa Russnak, Elise Wu, Sumesh Kachroo
Treatment Discontinuation in Inflammatory Bowel Disease (IBD) Patients Receiving Biologic Therapies That Require Intravenous (IV) Induction and Subcutaneous (SC) Maintenance Using Two Large US Claims Databases
Jennifer Seminerio, Yichen Zhang, Stephen Uong, Shashi Adsul, Gustavo Scapini, Christopher Busse, Sheetal P. Dharia, Xiaoxiao Alice Lu, Ryan Ungaro
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
